首页 > 最新文献

Journal of Basic and Clinical Physiology and Pharmacology最新文献

英文 中文
A critical comparison of pharmacovigilance reporting forms in six countries with the WHO-UMC recommendations (form of the form). 对6个国家的药物警戒报告表格与世卫组织-联合药检委员会的建议进行关键性比较(表格的形式)。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-07-17 eCollection Date: 2025-07-01 DOI: 10.1515/jbcpp-2025-0084
Saurav Misra, Manmeet Kaur, Jayant Kumar Kairi

Objectives: This study will identify strengths and weaknesses of ADR reporting forms of study countries.

Methods: This was an observational study conducted at the Department of Pharmacology at Kalpana Chawla Government Medical College, Karnal. We obtained the WHO-UMC adverse event reporting guidance document for designing the ADR form for member countries. We similarly collected and analysed ADR forms from Australia, Canada, India, South Africa, the UK, and the US. Data fields were grouped into different subgroups.

Results: An analysis of ADR reporting forms from six countries revealed a total of 70 data fields. The US-FDA's FORM 3500 has the most fields at 50 (71 %), followed by India's CDSCO with 42 fields (60 %). According to WHO-UMC recommendations, Canada and Australia have the highest number of suggested fields at 10 (83 %). All forms were one page long except for the US-FDA's, which is five pages.

Conclusions: Improving patient feedback and organisational engagement is essential to raise awareness of the reporting system. A proposed generic ADR form provides detailed information for causality assessment and could serve as a basis for a standard global reporting form.

目的:本研究将确定研究国家不良反应报告形式的优势和劣势。方法:这是一项在卡尔帕纳·舒拉政府医学院药学系进行的观察性研究。我们获得了世卫组织- umc不良事件报告指导文件,用于为成员国设计ADR表格。我们同样收集并分析了澳大利亚、加拿大、印度、南非、英国和美国的ADR表格。数据字段被分成不同的子组。结果:对来自6个国家的药品不良反应报告表进行分析,共发现70个数据字段。美国fda的FORM 3500拥有最多的领域,为50个(71 %),其次是印度的CDSCO,有42个领域(60 %)。根据世卫组织- umc的建议,加拿大和澳大利亚建议的领域最多,为10个(83% %)。所有的表格都是一页长,除了美国食品和药物管理局的表格是五页。结论:改善患者反馈和组织参与对提高对报告系统的认识至关重要。拟议的通用ADR表为因果关系评估提供了详细信息,并可作为标准全球报告表的基础。
{"title":"A critical comparison of pharmacovigilance reporting forms in six countries with the WHO-UMC recommendations (form of the form).","authors":"Saurav Misra, Manmeet Kaur, Jayant Kumar Kairi","doi":"10.1515/jbcpp-2025-0084","DOIUrl":"10.1515/jbcpp-2025-0084","url":null,"abstract":"<p><strong>Objectives: </strong>This study will identify strengths and weaknesses of ADR reporting forms of study countries.</p><p><strong>Methods: </strong>This was an observational study conducted at the Department of Pharmacology at Kalpana Chawla Government Medical College, Karnal. We obtained the WHO-UMC adverse event reporting guidance document for designing the ADR form for member countries. We similarly collected and analysed ADR forms from Australia, Canada, India, South Africa, the UK, and the US. Data fields were grouped into different subgroups.</p><p><strong>Results: </strong>An analysis of ADR reporting forms from six countries revealed a total of 70 data fields. The US-FDA's FORM 3500 has the most fields at 50 (71 %), followed by India's CDSCO with 42 fields (60 %). According to WHO-UMC recommendations, Canada and Australia have the highest number of suggested fields at 10 (83 %). All forms were one page long except for the US-FDA's, which is five pages.</p><p><strong>Conclusions: </strong>Improving patient feedback and organisational engagement is essential to raise awareness of the reporting system. A proposed generic ADR form provides detailed information for causality assessment and could serve as a basis for a standard global reporting form.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"285-294"},"PeriodicalIF":0.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic potential of resveratrol: novel biological and pharmacological perspectives. 白藜芦醇的治疗潜力:新的生物学和药理学观点。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-07-11 eCollection Date: 2025-09-01 DOI: 10.1515/jbcpp-2024-0211
Milad Ashrafizadeh

The application of natural occurring compounds in the treatment of human diseases has been increased in the recent decades due to the biocompatibility and pleiotropic impacts of these agents along with significant health-promoting effects. Among them, resveratrol has been shown to be of importance, since it can exert various biological and pharmacological activities. Moreover, resveratrol generally demonstrates good biosafety and biocompatibility that can further improve its application in clinical studies. In terms of biological activities, the antioxidant and anti-inflammatory activities of resveratrol has been of importance and they are useful in the prevention of diabetes and neurological diseases. The antioxidant activity of resveratrol can result from its function in enhancing levels of antioxidant factors such as catalase and superoxide dismutase, and reduction in ROS levels. Moreover, resveratrol can reduce inflammation and downregulate related pathways such as NF-κB. Beyond this, resveratrol has been shown to be beneficial in the treatment of human diseases such as diabetes mellitus, cancer (suppressing tumorigenesis or acting as chemopreventive agent) and alleviation of neurological diseases, among others. Such protective impacts of resveratrol would be discussed in the current review with a focus on underlying molecular factors. In addition, nanoparticles have been significantly applied in the treatment of human disease through delivery of resveratrol and since pharmacokinetic profile of resveratrol is poor, the application of delivery systems can accelerate therapeutic index of this natural product. However, clinical application of resveratrol-loaded nanoparticles in the clinical level relies on the biocomaptibility and safety of these structures along with their efficacy.

近几十年来,由于天然化合物的生物相容性和多效性以及显著的健康促进作用,它们在人类疾病治疗中的应用有所增加。其中,白藜芦醇已被证明是重要的,因为它可以发挥多种生物和药理活性。此外,白藜芦醇普遍具有良好的生物安全性和生物相容性,可以进一步提高其在临床研究中的应用。在生物活性方面,白藜芦醇的抗氧化和抗炎活性一直很重要,它们在预防糖尿病和神经系统疾病方面很有用。白藜芦醇具有提高过氧化氢酶和超氧化物歧化酶等抗氧化因子水平和降低活性氧水平的功能,具有抗氧化活性。此外,白藜芦醇还能减轻炎症,下调NF-κB等相关通路。除此之外,白藜芦醇已被证明有益于治疗人类疾病,如糖尿病、癌症(抑制肿瘤发生或作为化学预防剂)和减轻神经系统疾病等。白藜芦醇的这种保护作用将在本综述中讨论,重点是潜在的分子因素。此外,纳米颗粒通过白藜芦醇的递送已经在人类疾病的治疗中得到了显著的应用,由于白藜芦醇的药代动力学谱较差,应用递送系统可以加速这种天然产物的治疗指数。然而,装载白藜芦醇的纳米颗粒在临床水平上的应用依赖于这些结构的生物相容性和安全性以及它们的有效性。
{"title":"<b>Therapeutic potential of</b> r<b>esveratrol:</b> n<b>ovel</b> b<b>iological and</b> p<b>harmacological</b> p<b>erspectives</b>.","authors":"Milad Ashrafizadeh","doi":"10.1515/jbcpp-2024-0211","DOIUrl":"10.1515/jbcpp-2024-0211","url":null,"abstract":"<p><p>The application of natural occurring compounds in the treatment of human diseases has been increased in the recent decades due to the biocompatibility and pleiotropic impacts of these agents along with significant health-promoting effects. Among them, resveratrol has been shown to be of importance, since it can exert various biological and pharmacological activities. Moreover, resveratrol generally demonstrates good biosafety and biocompatibility that can further improve its application in clinical studies. In terms of biological activities, the antioxidant and anti-inflammatory activities of resveratrol has been of importance and they are useful in the prevention of diabetes and neurological diseases. The antioxidant activity of resveratrol can result from its function in enhancing levels of antioxidant factors such as catalase and superoxide dismutase, and reduction in ROS levels. Moreover, resveratrol can reduce inflammation and downregulate related pathways such as NF-κB. Beyond this, resveratrol has been shown to be beneficial in the treatment of human diseases such as diabetes mellitus, cancer (suppressing tumorigenesis or acting as chemopreventive agent) and alleviation of neurological diseases, among others. Such protective impacts of resveratrol would be discussed in the current review with a focus on underlying molecular factors. In addition, nanoparticles have been significantly applied in the treatment of human disease through delivery of resveratrol and since pharmacokinetic profile of resveratrol is poor, the application of delivery systems can accelerate therapeutic index of this natural product. However, clinical application of resveratrol-loaded nanoparticles in the clinical level relies on the biocomaptibility and safety of these structures along with their efficacy.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"301-318"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Future therapeutic perspectives of BCG therapy for bladder cancer: an evolving horizon. 卡介苗治疗膀胱癌的未来治疗前景:一个不断发展的视野。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-07-01 DOI: 10.1515/jbcpp-2025-0106
Michele Musone, Stefano Chianese, Ciro Chervino, Antonio Madonna, Tiziana Rotunno
{"title":"Future therapeutic perspectives of BCG therapy for bladder cancer: an evolving horizon.","authors":"Michele Musone, Stefano Chianese, Ciro Chervino, Antonio Madonna, Tiziana Rotunno","doi":"10.1515/jbcpp-2025-0106","DOIUrl":"10.1515/jbcpp-2025-0106","url":null,"abstract":"","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"243-245"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insight into novel therapeutic targets in heart failure: a comprehensive review. 心力衰竭新治疗靶点的研究综述
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-06-11 eCollection Date: 2025-07-01 DOI: 10.1515/jbcpp-2024-0234
Dalia O Saleh, Ahmed A Sedik

Heart failure (HF) represents the final manifestation of various cardiovascular diseases, emerging as a significant global health challenge that impacts over 20 million individuals worldwide. This review provides a comprehensive overview of the latest pharmacological agents developed to address HF, focusing on their effectiveness in alleviating symptoms associated with the condition. It highlights the critical necessity for a more profound understanding of the multifaceted processes and pathways that contribute to HF pathogenesis. The methodology employed in this review demonstrates encouraging outcomes from numerous pharmaceutical agents evaluated for their ability to relieve HF symptoms, showcasing their effectiveness in improving patient experiences. However, a significant gap remains in tackling the fundamental issues underlying HF. The findings emphasize the intricate nature of HF and the obstacles faced in creating therapies that extend beyond mere symptomatic management. Currently, the predominant approach to HF treatment involves targeting the underlying mechanisms of the disease and addressing related neurohumoral imbalances. Despite the growing arsenal of treatments available for HF, patient outcomes continue to be suboptimal. Therefore, this review aims to illuminate potential therapeutic targets for more effective management strategies for HF, ultimately striving to enhance patient prognosis and quality of life.

心力衰竭(HF)是各种心血管疾病的最终表现,已成为影响全球2000多万人的重大全球健康挑战。本文综述了治疗心衰的最新药物,重点介绍了它们在缓解心衰相关症状方面的有效性。它强调了对促成心衰发病机制的多方面过程和途径进行更深刻理解的关键必要性。本综述采用的方法表明,许多药物制剂在缓解心衰症状方面的能力得到了令人鼓舞的结果,显示了它们在改善患者体验方面的有效性。然而,在解决HF的根本问题方面仍然存在重大差距。这些发现强调了心衰复杂的本质,以及在创造超越单纯症状管理的治疗方法时所面临的障碍。目前,心衰治疗的主要方法包括针对疾病的潜在机制和解决相关的神经体液失衡。尽管心衰的治疗方法越来越多,但患者的预后仍然不理想。因此,本综述旨在阐明心衰的潜在治疗靶点,制定更有效的治疗策略,最终努力改善患者预后和生活质量。
{"title":"Insight into novel therapeutic targets in heart failure: a comprehensive review.","authors":"Dalia O Saleh, Ahmed A Sedik","doi":"10.1515/jbcpp-2024-0234","DOIUrl":"10.1515/jbcpp-2024-0234","url":null,"abstract":"<p><p>Heart failure (HF) represents the final manifestation of various cardiovascular diseases, emerging as a significant global health challenge that impacts over 20 million individuals worldwide. This review provides a comprehensive overview of the latest pharmacological agents developed to address HF, focusing on their effectiveness in alleviating symptoms associated with the condition. It highlights the critical necessity for a more profound understanding of the multifaceted processes and pathways that contribute to HF pathogenesis. The methodology employed in this review demonstrates encouraging outcomes from numerous pharmaceutical agents evaluated for their ability to relieve HF symptoms, showcasing their effectiveness in improving patient experiences. However, a significant gap remains in tackling the fundamental issues underlying HF. The findings emphasize the intricate nature of HF and the obstacles faced in creating therapies that extend beyond mere symptomatic management. Currently, the predominant approach to HF treatment involves targeting the underlying mechanisms of the disease and addressing related neurohumoral imbalances. Despite the growing arsenal of treatments available for HF, patient outcomes continue to be suboptimal. Therefore, this review aims to illuminate potential therapeutic targets for more effective management strategies for HF, ultimately striving to enhance patient prognosis and quality of life.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"247-262"},"PeriodicalIF":0.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lymph node ultrasound in lymphoproliferative disorders: clinical characteristics and applications. 淋巴结超声在淋巴增生性疾病中的临床特点及应用。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-06-03 eCollection Date: 2025-07-01 DOI: 10.1515/jbcpp-2025-0089
Rita Tavarozzi, Anna Lombardi, Ferdinando Scarano, Laura Staiano, Gerardo Trattelli, Michela Farro, Alessia Castellino, Carmine Coppola

Introduction: Superficial lymph node (LN) enlargement is a common ultrasonographic finding and can be associated with a broad spectrum of conditions, from benign reactive hyperplasia to malignant lymphoproliferative disorders (LPDs). LPDs, which include various hematologic malignancies affecting lymphoid tissue, present with diverse immune-morphological and clinical features, making differentiation from other malignant causes of lymphadenopathy challenging.

Content: Radiologic assessment is crucial in characterizing lymphadenopathy, with ultrasonography serving as a noninvasive and widely available imaging modality. High-resolution ultrasound allows the evaluation of key features such as LN size, shape, border definition, echogenicity, and the presence of abnormal cortical thickening, loss of the fatty hilum, or altered vascular patterns, which aid in distinguishing benign from malignant processes.

Summary: This review aims to describe the ultrasonographic characteristics of lymphadenopathy, offering essential diagnostic insights to differentiate malignant disorders, particularly LPDs. We will discuss standard ultrasound techniques, including grayscale imaging and Doppler ultrasound, and explore more advanced methods such as contrast-enhanced ultrasound (CEUS), elastography, and artificial intelligence-assisted imaging, which are gaining prominence in LN evaluation.

Outlook: By highlighting these imaging modalities, we aim to enhance the diagnostic accuracy of ultrasonography in lymphadenopathy assessment and improve early detection of LPDs and other malignant conditions.

简介:浅表淋巴结(LN)肿大是一种常见的超声检查结果,可与多种疾病相关,从良性反应性增生到恶性淋巴细胞增生性疾病(lpd)。lpd包括影响淋巴组织的各种血液恶性肿瘤,具有不同的免疫形态学和临床特征,使得与其他恶性淋巴结病的区分具有挑战性。内容:影像学评估对淋巴结病变的特征至关重要,超声检查是一种无创且广泛使用的成像方式。高分辨率超声可以评估关键特征,如LN的大小、形状、边界定义、回声强度、异常皮质增厚、脂肪门缺失或血管模式改变的存在,这有助于区分良性和恶性病变。摘要:本综述旨在描述淋巴结病的超声特征,为鉴别恶性疾病,特别是lpd提供必要的诊断见解。我们将讨论标准超声技术,包括灰度成像和多普勒超声,并探索更先进的方法,如对比增强超声(CEUS)、弹性成像和人工智能辅助成像,这些方法在LN评估中越来越突出。展望:通过强调这些成像方式,我们旨在提高超声检查在淋巴结病评估中的诊断准确性,提高对lpd和其他恶性疾病的早期发现。
{"title":"Lymph node ultrasound in lymphoproliferative disorders: clinical characteristics and applications.","authors":"Rita Tavarozzi, Anna Lombardi, Ferdinando Scarano, Laura Staiano, Gerardo Trattelli, Michela Farro, Alessia Castellino, Carmine Coppola","doi":"10.1515/jbcpp-2025-0089","DOIUrl":"10.1515/jbcpp-2025-0089","url":null,"abstract":"<p><strong>Introduction: </strong>Superficial lymph node (LN) enlargement is a common ultrasonographic finding and can be associated with a broad spectrum of conditions, from benign reactive hyperplasia to malignant lymphoproliferative disorders (LPDs). LPDs, which include various hematologic malignancies affecting lymphoid tissue, present with diverse immune-morphological and clinical features, making differentiation from other malignant causes of lymphadenopathy challenging.</p><p><strong>Content: </strong>Radiologic assessment is crucial in characterizing lymphadenopathy, with ultrasonography serving as a noninvasive and widely available imaging modality. High-resolution ultrasound allows the evaluation of key features such as LN size, shape, border definition, echogenicity, and the presence of abnormal cortical thickening, loss of the fatty hilum, or altered vascular patterns, which aid in distinguishing benign from malignant processes.</p><p><strong>Summary: </strong>This review aims to describe the ultrasonographic characteristics of lymphadenopathy, offering essential diagnostic insights to differentiate malignant disorders, particularly LPDs. We will discuss standard ultrasound techniques, including grayscale imaging and Doppler ultrasound, and explore more advanced methods such as contrast-enhanced ultrasound (CEUS), elastography, and artificial intelligence-assisted imaging, which are gaining prominence in LN evaluation.</p><p><strong>Outlook: </strong>By highlighting these imaging modalities, we aim to enhance the diagnostic accuracy of ultrasonography in lymphadenopathy assessment and improve early detection of LPDs and other malignant conditions.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"275-284"},"PeriodicalIF":0.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The pharmacokinetics and comparative bioavailabilty of oral and subcutaneous semaglutide in healthy volunteers. 健康志愿者口服和皮下注射西马鲁肽的药代动力学和比较生物利用度。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-05-26 eCollection Date: 2025-03-01 DOI: 10.1515/jbcpp-2025-0026
Mohammed Bouhajib, Zia Tayab, Chantal Di Marco, Dennis Dong-Kyun Suh

Objectives: In this study, the comparative bioavailability of semaglutide following the administration of oral (PO) and subcutaneous (SC) doses in healthy subjects was evaluated. The pharmacokinetics of semaglutide of these formulations at lower doses (SC dose of 0.25 mg; PO dose of 3 mg) was examined by utilizing a sensitive bioanalytical method.

Methods: Twenty-two subjects were administered either 0.25 mg SC or 3 mg PO and blood samples were taken up to 504 h. The samples were assayed for semaglutide with an analytical range of 0.05-50 ng/mL. The pharmacokinetic parameters were estimated using a non-compartmental approach and were used to evaluate the comparative bioavailability of semaglutide.

Results: The pharmacokinetics of semaglutide was characterized following the administration of low subcutaneous and oral doses. The comparative bioavailability (PO relative to SC) was 0.66 % at the doses administered. Overall, the study drug was well tolerated, and no serious adverse events were reported.

Conclusions: The bioavailability of semaglutide following oral and subcutaneous administrations has been determined using a validated bioanalytical method. This method will enable more investigations into the pharmacokinetics of all formulations of semaglutide at lower doses, which will enable a better understanding of its' disposition in healthy subjects and in patients.

目的:在本研究中,对健康受试者口服(PO)和皮下(SC)给药后的西马鲁肽的比较生物利用度进行了评估。低剂量(SC剂量为0.25 mg;采用灵敏的生物分析方法检测PO剂量(3 mg)。方法:22名受试者分别给予0.25 mg SC或3 mg PO,采集血样至504 h。检测样品的semaglutide,分析范围为0.05-50 ng/mL。使用非室室方法估计药代动力学参数,并用于评估semaglutide的比较生物利用度。结果:低剂量皮下和口服给药对西马鲁肽的药代动力学有明显影响。在给药剂量下,比较生物利用度(PO相对于SC)为0.66 %。总的来说,研究药物耐受性良好,没有严重不良事件的报道。结论:用一种有效的生物分析方法测定了口服和皮下给药后的西马鲁肽的生物利用度。该方法将使我们能够在低剂量下对所有西马鲁肽制剂的药代动力学进行更多的研究,从而更好地了解其在健康受试者和患者中的倾向。
{"title":"The pharmacokinetics and comparative bioavailabilty of oral and subcutaneous semaglutide in healthy volunteers.","authors":"Mohammed Bouhajib, Zia Tayab, Chantal Di Marco, Dennis Dong-Kyun Suh","doi":"10.1515/jbcpp-2025-0026","DOIUrl":"10.1515/jbcpp-2025-0026","url":null,"abstract":"<p><strong>Objectives: </strong>In this study, the comparative bioavailability of semaglutide following the administration of oral (PO) and subcutaneous (SC) doses in healthy subjects was evaluated. The pharmacokinetics of semaglutide of these formulations at lower doses (SC dose of 0.25 mg; PO dose of 3 mg) was examined by utilizing a sensitive bioanalytical method.</p><p><strong>Methods: </strong>Twenty-two subjects were administered either 0.25 mg SC or 3 mg PO and blood samples were taken up to 504 h. The samples were assayed for semaglutide with an analytical range of 0.05-50 ng/mL. The pharmacokinetic parameters were estimated using a non-compartmental approach and were used to evaluate the comparative bioavailability of semaglutide.</p><p><strong>Results: </strong>The pharmacokinetics of semaglutide was characterized following the administration of low subcutaneous and oral doses. The comparative bioavailability (PO relative to SC) was 0.66 % at the doses administered. Overall, the study drug was well tolerated, and no serious adverse events were reported.</p><p><strong>Conclusions: </strong>The bioavailability of semaglutide following oral and subcutaneous administrations has been determined using a validated bioanalytical method. This method will enable more investigations into the pharmacokinetics of all formulations of semaglutide at lower doses, which will enable a better understanding of its' disposition in healthy subjects and in patients.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"221-227"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current trends and innovations in oral and maxillofacial surgery. 口腔颌面外科的最新趋势和创新。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-05-22 eCollection Date: 2025-03-01 DOI: 10.1515/jbcpp-2025-0042
Giovanni Salzano, Francesco Maffia, Giovanni Dell'Aversana Orabona

Objectives: This manuscript reviews advancements in oral and maxillofacial surgery, encompassing minimally invasive techniques, innovations in implant dentistry, regenerative medicine, innovations in temporomandibular joint, and novel methodologies in salivary gland surgery.

Methods: A comprehensive analysis of recent developments in the field is presented, focusing on the integration of new technologies and biological therapies. Emphasis is placed on minimally invasive procedures, virtual surgical planning with CAD/CAM and 3D printing, implant design and placement innovations, and regenerative approaches.

Results: Minimally invasive procedures, often employing endoscopic or robotic assistance, reduce surgical morbidity and accelerate patient recovery. Virtual surgical planning and 3D printing enhance pre-surgical accuracy. Innovations in implant design, surface modification, and guided surgery improve prosthetic outcomes. Regenerative medicine and tissue engineering, including the use of growth factors and stem cells, offer new options for tissue restoration. In temporomandibular joint disorders, these strategies aim to improve function and reduce reliance on arthroplasty. The use of superficial dermal substitutes in salivary gland surgery reduces complications such as Frey syndrome.

Conclusions: These advancements reflect a paradigm shift in oral and maxillofacial surgery, enhancing patient care and expanding the field's potential through precision, biologically based therapies, and less invasive approaches.

目的:本文回顾了口腔颌面外科的进展,包括微创技术、种植牙科的创新、再生医学、颞下颌关节的创新和唾液腺手术的新方法。方法:综合分析该领域的最新发展,重点是新技术和生物疗法的结合。重点放在微创手术、CAD/CAM和3D打印的虚拟手术计划、植入物设计和放置创新以及再生方法上。结果:微创手术,通常采用内镜或机器人辅助,减少手术发病率,加速患者康复。虚拟手术计划和3D打印提高了手术前的准确性。种植体设计、表面修饰和引导手术的创新改善了假体的效果。再生医学和组织工程,包括生长因子和干细胞的使用,为组织修复提供了新的选择。在颞下颌关节疾病中,这些策略旨在改善功能并减少对关节置换术的依赖。在唾液腺手术中使用浅表真皮代用品可减少诸如弗雷综合征等并发症。结论:这些进展反映了口腔颌面外科的范式转变,通过精确、基于生物学的治疗和微创方法,加强了患者护理,扩大了该领域的潜力。
{"title":"Current trends and innovations in oral and maxillofacial surgery.","authors":"Giovanni Salzano, Francesco Maffia, Giovanni Dell'Aversana Orabona","doi":"10.1515/jbcpp-2025-0042","DOIUrl":"10.1515/jbcpp-2025-0042","url":null,"abstract":"<p><strong>Objectives: </strong>This manuscript reviews advancements in oral and maxillofacial surgery, encompassing minimally invasive techniques, innovations in implant dentistry, regenerative medicine, innovations in temporomandibular joint, and novel methodologies in salivary gland surgery.</p><p><strong>Methods: </strong>A comprehensive analysis of recent developments in the field is presented, focusing on the integration of new technologies and biological therapies. Emphasis is placed on minimally invasive procedures, virtual surgical planning with CAD/CAM and 3D printing, implant design and placement innovations, and regenerative approaches.</p><p><strong>Results: </strong>Minimally invasive procedures, often employing endoscopic or robotic assistance, reduce surgical morbidity and accelerate patient recovery. Virtual surgical planning and 3D printing enhance pre-surgical accuracy. Innovations in implant design, surface modification, and guided surgery improve prosthetic outcomes. Regenerative medicine and tissue engineering, including the use of growth factors and stem cells, offer new options for tissue restoration. In temporomandibular joint disorders, these strategies aim to improve function and reduce reliance on arthroplasty. The use of superficial dermal substitutes in salivary gland surgery reduces complications such as Frey syndrome.</p><p><strong>Conclusions: </strong>These advancements reflect a paradigm shift in oral and maxillofacial surgery, enhancing patient care and expanding the field's potential through precision, biologically based therapies, and less invasive approaches.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"237-240"},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical significance of detectable blood lead and cadmium in the Sarno river basin population: results from the PREVES-STOP study. 萨尔诺河流域人群可检测血铅和镉的临床意义:prees - stop研究结果
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-05-07 eCollection Date: 2025-03-01 DOI: 10.1515/jbcpp-2025-0037
Giuseppe Di Lorenzo, Carlo Buonerba, Felice Crocetto, Raffaele Baio, Antonio Verde, Vittorino Montanaro, Federica Fortino, Alessia N Calabrese, Concetta Ingenito, Rossella Di Trolio, Serena Rizzano, Armando Pisapia, Vittorio Riccio, Emma Costa, Giovanni Riccio, Carla Errico, Francesco Del Giudice, Antonio Aliberti, Ferdinando Costabile, Giuseppina Busto, Annamaria Libroia, Antonio Coppola, Arcangelo Saggese Tozzi, Oriana Strianese, Luca Scafuri

Objectives: The Sarno river basin (Italy) is a region characterized by significant environmental pollution, raising concerns about heavy metal exposure in residents. The PREVES-STOP Initiative aims to address these concerns. This study investigates the prevalence of detectable blood lead (Pb) and cadmium (Cd) in a cohort of adults from this area and examines associations with key health indicators.

Methods: This study analyzed data from 75 adults (aged 30-65) participating in the PREVES-STOP Initiative. Participants completed comprehensive questionnaires assessing demographics, medical history, lifestyle factors (smoking, physical activity), and psychometric measures (fatigue, anxiety/depression, sleep quality). Blood samples were analyzed for Pb and Cd using established methods, with detectable levels defined as≥2 μg/100 mL (Pb) and ≥0.5 μg/L (Cd).

Results: Detectable Pb (18.67 % of participants) was significantly associated with higher systolic blood pressure, hemoglobin, and MCH, and inversely correlated with HDL cholesterol. Poorer sleep quality was also associated with detectable Pb. Detectable Cd (28 % of participants) was significantly associated with higher systolic blood pressure, LDL cholesterol, neutrophil count, and with higher odds of having a history of autoimmune diseases. Multivariate regression models, adjusting for age, sex, smoking status, and BMI, were used to determine these associations.

Conclusions: This study demonstrates that even low-level exposure to Pb and Cd in the Sarno river basin is associated with adverse clinical outcomes. The PREVES-STOP Initiative provides a valuable framework for community-based health assessment and intervention in areas affected by environmental pollution.

目的:萨尔诺河流域(意大利)是一个环境污染严重的地区,引起了人们对居民重金属暴露的关注。预防-停止倡议旨在解决这些问题。本研究调查了该地区成人队列中可检测血铅(Pb)和镉(Cd)的流行情况,并检查了与关键健康指标的关系。方法:本研究分析了参加prees - stop倡议的75名成年人(30-65岁)的数据。参与者完成了全面的问卷调查,评估人口统计、病史、生活方式因素(吸烟、体育活动)和心理测量指标(疲劳、焦虑/抑郁、睡眠质量)。采用既定方法分析血样中的Pb和Cd,检测水平定义为≥2 μg/100 mL (Pb)和≥0.5 μg/L (Cd)。结果:可检测到的铅(18.67 %的参与者)与较高的收缩压、血红蛋白和MCH显著相关,与高密度脂蛋白胆固醇呈负相关。较差的睡眠质量也与可检测到的铅有关。可检测到的Cd(28% %的参与者)与较高的收缩压、低密度脂蛋白胆固醇、中性粒细胞计数以及具有自身免疫性疾病史的较高几率显著相关。使用多变量回归模型,调整年龄、性别、吸烟状况和BMI来确定这些关联。结论:本研究表明,即使在Sarno河流域低水平暴露于Pb和Cd也与不良临床结果有关。预防-停止倡议为受环境污染影响地区的社区健康评估和干预提供了一个宝贵的框架。
{"title":"Clinical significance of detectable blood lead and cadmium in the Sarno river basin population: results from the PREVES-STOP study.","authors":"Giuseppe Di Lorenzo, Carlo Buonerba, Felice Crocetto, Raffaele Baio, Antonio Verde, Vittorino Montanaro, Federica Fortino, Alessia N Calabrese, Concetta Ingenito, Rossella Di Trolio, Serena Rizzano, Armando Pisapia, Vittorio Riccio, Emma Costa, Giovanni Riccio, Carla Errico, Francesco Del Giudice, Antonio Aliberti, Ferdinando Costabile, Giuseppina Busto, Annamaria Libroia, Antonio Coppola, Arcangelo Saggese Tozzi, Oriana Strianese, Luca Scafuri","doi":"10.1515/jbcpp-2025-0037","DOIUrl":"10.1515/jbcpp-2025-0037","url":null,"abstract":"<p><strong>Objectives: </strong>The Sarno river basin (Italy) is a region characterized by significant environmental pollution, raising concerns about heavy metal exposure in residents. The PREVES-STOP Initiative aims to address these concerns. This study investigates the prevalence of detectable blood lead (Pb) and cadmium (Cd) in a cohort of adults from this area and examines associations with key health indicators.</p><p><strong>Methods: </strong>This study analyzed data from 75 adults (aged 30-65) participating in the PREVES-STOP Initiative. Participants completed comprehensive questionnaires assessing demographics, medical history, lifestyle factors (smoking, physical activity), and psychometric measures (fatigue, anxiety/depression, sleep quality). Blood samples were analyzed for Pb and Cd using established methods, with detectable levels defined as≥2 μg/100 mL (Pb) and ≥0.5 μg/L (Cd).</p><p><strong>Results: </strong>Detectable Pb (18.67 % of participants) was significantly associated with higher systolic blood pressure, hemoglobin, and MCH, and inversely correlated with HDL cholesterol. Poorer sleep quality was also associated with detectable Pb. Detectable Cd (28 % of participants) was significantly associated with higher systolic blood pressure, LDL cholesterol, neutrophil count, and with higher odds of having a history of autoimmune diseases. Multivariate regression models, adjusting for age, sex, smoking status, and BMI, were used to determine these associations.</p><p><strong>Conclusions: </strong>This study demonstrates that even low-level exposure to Pb and Cd in the Sarno river basin is associated with adverse clinical outcomes. The PREVES-STOP Initiative provides a valuable framework for community-based health assessment and intervention in areas affected by environmental pollution.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"203-213"},"PeriodicalIF":0.0,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucagon in glucose homeostasis and metabolic disease: from physiology to therapeutics. 胰高血糖素在葡萄糖稳态和代谢疾病中的作用:从生理学到治疗学。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-05-05 eCollection Date: 2025-03-01 DOI: 10.1515/jbcpp-2025-0005
Abdulbasit Amin, Toyin Mohammed Salman

Glucagon, a key hormone in glucose homeostasis, plays a central role in maintaining blood glucose levels through hepatic glycogenolysis and gluconeogenesis. Historically, glucagon secretion was believed to be primarily regulated by insulin via the "insulin switch-off" hypothesis, where reduced insulin levels triggered glucagon release. However, this view has been revisited as emerging evidence highlights the complexity of glucagon regulation. New studies demonstrate that glucose itself, along with amino acids and fatty acid oxidation, directly influences glucagon secretion, challenging the insulin-centric perspective. These findings reveal the metabolic versatility of pancreatic α-cells and their capacity to adapt to nutrient availability. Recent therapeutic innovations, such as glucagon receptor antagonists, dual GLP-1/glucagon receptor agonists, and modulators of hepatic glucagon signalling, offer promising strategies to mitigate hyperglycemia, improve energy balance, and address metabolic dysregulation. This review provides an in-depth analysis of glucagon's role in health and disease, emphasizing its therapeutic potential in managing diabetes and related metabolic conditions.

胰高血糖素是葡萄糖稳态的关键激素,通过肝糖原分解和糖异生在维持血糖水平中起核心作用。从历史上看,人们认为胰高血糖素的分泌主要是由胰岛素通过“胰岛素关闭”假说来调节的,即胰岛素水平降低会触发胰高血糖素的释放。然而,随着新出现的证据强调胰高血糖素调节的复杂性,这一观点已被重新审视。新的研究表明,葡萄糖本身,以及氨基酸和脂肪酸氧化,直接影响胰高血糖素的分泌,挑战了以胰岛素为中心的观点。这些发现揭示了胰腺α-细胞的代谢多样性及其适应营养可利用性的能力。最近的治疗创新,如胰高血糖素受体拮抗剂、双GLP-1/胰高血糖素受体激动剂和肝胰高血糖素信号调节剂,为减轻高血糖、改善能量平衡和解决代谢失调提供了有希望的策略。这篇综述深入分析了胰高血糖素在健康和疾病中的作用,强调了其在治疗糖尿病和相关代谢疾病中的治疗潜力。
{"title":"Glucagon in glucose homeostasis and metabolic disease: from physiology to therapeutics.","authors":"Abdulbasit Amin, Toyin Mohammed Salman","doi":"10.1515/jbcpp-2025-0005","DOIUrl":"10.1515/jbcpp-2025-0005","url":null,"abstract":"<p><p>Glucagon, a key hormone in glucose homeostasis, plays a central role in maintaining blood glucose levels through hepatic glycogenolysis and gluconeogenesis. Historically, glucagon secretion was believed to be primarily regulated by insulin via the \"insulin switch-off\" hypothesis, where reduced insulin levels triggered glucagon release. However, this view has been revisited as emerging evidence highlights the complexity of glucagon regulation. New studies demonstrate that glucose itself, along with amino acids and fatty acid oxidation, directly influences glucagon secretion, challenging the insulin-centric perspective. These findings reveal the metabolic versatility of pancreatic α-cells and their capacity to adapt to nutrient availability. Recent therapeutic innovations, such as glucagon receptor antagonists, dual GLP-1/glucagon receptor agonists, and modulators of hepatic glucagon signalling, offer promising strategies to mitigate hyperglycemia, improve energy balance, and address metabolic dysregulation. This review provides an in-depth analysis of glucagon's role in health and disease, emphasizing its therapeutic potential in managing diabetes and related metabolic conditions.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"139-146"},"PeriodicalIF":0.0,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of heavy metals exposure on male fertility: a scoping review of human studies. 重金属暴露对男性生育能力的影响:人类研究的范围审查。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-04-22 eCollection Date: 2025-03-01 DOI: 10.1515/jbcpp-2025-0049
Carlo Giulioni, Federico Falsetti, Valentina Maurizi, Francesco Del Giudice, Felice Crocetto, Ciro Imbimbo, Angelo Cafarelli

Introduction: Male infertility is a critical global health issue, with environmental and occupational exposure to heavy metals, such as lead (Pb), cadmium (Cd), mercury (Hg), and arsenic (As), impacting male reproductive health. This scoping review aims to evaluate the effects of heavy metal exposure on semen parameters.

Content: This study adhered to the 2020 PRISMA framework. A broad literature search was performed on January 2025, using Embase, PUBMED, and Scopus. A comprehensive literature search was performed using PubMed, Embase, and Scopus on January 12, 2025, using a combination of Medical Subject terms and keywords.

Summary: Of the 1,709 identified studies, 21 met the inclusion criteria and were analyzed. Findings indicate that lead exposure negatively impacts sperm concentration, motility, and morphology, primarily through oxidative stress and enzymatic inhibition. Cadmium disrupts the blood-testis barrier and acrosomal function, leading to sperm abnormalities. Arsenic exposure is linked to oxidative stress, apoptosis, and impaired sperm motility.

Outlook: The cumulative evidence supports a strong association between heavy metal exposure and male infertility. This review underscores the need for stricter occupational safety regulations and environmental policies to mitigate heavy metal exposure.

导言:男性不育是一个严重的全球健康问题,环境和职业暴露于重金属,如铅(Pb)、镉(Cd)、汞(Hg)和砷(as),影响男性生殖健康。本综述旨在评价重金属暴露对精液参数的影响。内容:本研究遵循2020 PRISMA框架。于2025年1月使用Embase、PUBMED和Scopus进行了广泛的文献检索。在2025年1月12日使用PubMed、Embase和Scopus进行了全面的文献检索,使用医学主题术语和关键字的组合。总结:在1709项研究中,21项符合纳入标准并被分析。研究结果表明,铅暴露主要通过氧化应激和酶抑制对精子浓度、活力和形态产生负面影响。镉破坏血睾丸屏障和顶体功能,导致精子异常。砷暴露与氧化应激、细胞凋亡和精子活力受损有关。展望:累积证据支持重金属暴露与男性不育之间的强烈关联。这一审查强调需要制定更严格的职业安全法规和环境政策,以减轻重金属暴露。
{"title":"The impact of heavy metals exposure on male fertility: a scoping review of human studies.","authors":"Carlo Giulioni, Federico Falsetti, Valentina Maurizi, Francesco Del Giudice, Felice Crocetto, Ciro Imbimbo, Angelo Cafarelli","doi":"10.1515/jbcpp-2025-0049","DOIUrl":"10.1515/jbcpp-2025-0049","url":null,"abstract":"<p><strong>Introduction: </strong>Male infertility is a critical global health issue, with environmental and occupational exposure to heavy metals, such as lead (Pb), cadmium (Cd), mercury (Hg), and arsenic (As), impacting male reproductive health. This scoping review aims to evaluate the effects of heavy metal exposure on semen parameters.</p><p><strong>Content: </strong>This study adhered to the 2020 PRISMA framework. A broad literature search was performed on January 2025, using Embase, PUBMED, and Scopus. A comprehensive literature search was performed using PubMed, Embase, and Scopus on January 12, 2025, using a combination of Medical Subject terms and keywords.</p><p><strong>Summary: </strong>Of the 1,709 identified studies, 21 met the inclusion criteria and were analyzed. Findings indicate that lead exposure negatively impacts sperm concentration, motility, and morphology, primarily through oxidative stress and enzymatic inhibition. Cadmium disrupts the blood-testis barrier and acrosomal function, leading to sperm abnormalities. Arsenic exposure is linked to oxidative stress, apoptosis, and impaired sperm motility.</p><p><strong>Outlook: </strong>The cumulative evidence supports a strong association between heavy metal exposure and male infertility. This review underscores the need for stricter occupational safety regulations and environmental policies to mitigate heavy metal exposure.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"129-137"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Basic and Clinical Physiology and Pharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1